Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1951 1
1952 1
1953 1
1956 1
1957 1
1958 2
1959 2
1960 2
1961 1
1962 1
1963 1
1964 6
1965 2
1966 7
1967 12
1968 14
1969 6
1970 8
1971 9
1972 8
1973 11
1974 7
1975 13
1976 17
1977 14
1978 16
1979 21
1980 26
1981 23
1982 18
1983 20
1984 17
1985 28
1986 16
1987 29
1988 24
1989 15
1990 32
1991 27
1992 40
1993 49
1994 47
1995 57
1996 53
1997 50
1998 55
1999 44
2000 47
2001 62
2002 59
2003 55
2004 64
2005 82
2006 88
2007 75
2008 101
2009 78
2010 80
2011 102
2012 99
2013 120
2014 154
2015 129
2016 134
2017 131
2018 124
2019 141
2020 156
2021 214
2022 185
2023 170
2024 157

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,333 results

Results by year

Filters applied: . Clear all
Page 1
Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations.
AAAAI/ACAAI JTF Atopic Dermatitis Guideline Panel; Chu DK, Schneider L, Asiniwasis RN, Boguniewicz M, De Benedetto A, Ellison K, Frazier WT, Greenhawt M, Huynh J, Kim E, LeBovidge J, Lind ML, Lio P, Martin SA, O'Brien M, Ong PY, Silverberg JI, Spergel JM, Wang J, Wheeler KE, Guyatt GH; Patient Groups: Global Parents for Eczema Research; Capozza K; National Eczema Association; Begolka WS; Evidence in Allergy Group; Chu AWL, Zhao IX, Chen L, Oykhman P, Bakaa L; AAAAI/ACAAI Joint Task Force on Practice Parameters; Golden D, Shaker M, Bernstein JA, Greenhawt M, Horner CC, Lieberman J, Stukus D, Rank MA, Wang J, Ellis A, Abrams E, Ledford D, Chu DK. AAAAI/ACAAI JTF Atopic Dermatitis Guideline Panel, et al. Among authors: o brien m. Ann Allergy Asthma Immunol. 2024 Mar;132(3):274-312. doi: 10.1016/j.anai.2023.11.009. Epub 2023 Dec 18. Ann Allergy Asthma Immunol. 2024. PMID: 38108679
Cardiovascular Pharmacology.
Mason JM, O'Brien ME, Koehl JL, Ji CS, Hayes BD. Mason JM, et al. Among authors: o brien me. Emerg Med Clin North Am. 2022 Nov;40(4):771-792. doi: 10.1016/j.emc.2022.06.012. Epub 2022 Oct 7. Emerg Med Clin North Am. 2022. PMID: 36396221 Review.
Allergen immunotherapy for atopic dermatitis: Systematic review and meta-analysis of benefits and harms.
Yepes-Nuñez JJ, Guyatt GH, Gómez-Escobar LG, Pérez-Herrera LC, Chu AWL, Ceccaci R, Acosta-Madiedo AS, Wen A, Moreno-López S, MacDonald M, Barrios M, Chu X, Islam N, Gao Y, Wong MM, Couban R, Garcia E, Chapman E, Oykhman P, Chen L, Winders T, Asiniwasis RN, Boguniewicz M, De Benedetto A, Ellison K, Frazier WT, Greenhawt M, Huynh J, Kim E, LeBovidge J, Lind ML, Lio P, Martin SA, O'Brien M, Ong PY, Silverberg JI, Spergel J, Wang J, Wheeler KE, Schneider L, Chu DK. Yepes-Nuñez JJ, et al. Among authors: o brien m. J Allergy Clin Immunol. 2023 Jan;151(1):147-158. doi: 10.1016/j.jaci.2022.09.020. Epub 2022 Sep 30. J Allergy Clin Immunol. 2023. PMID: 36191689 Free article.
Assessing the landscape of STXBP1-related disorders in 534 individuals.
Xian J, Parthasarathy S, Ruggiero SM, Balagura G, Fitch E, Helbig K, Gan J, Ganesan S, Kaufman MC, Ellis CA, Lewis-Smith D, Galer P, Cunningham K, O'Brien M, Cosico M, Baker K, Darling A, Veiga de Goes F, El Achkar CM, Doering JH, Furia F, García-Cazorla Á, Gardella E, Geertjens L, Klein C, Kolesnik-Taylor A, Lammertse H, Lee J, Mackie A, Misra-Isrie M, Olson H, Sexton E, Sheidley B, Smith L, Sotero L, Stamberger H, Syrbe S, Thalwitzer KM, van Berkel A, van Haelst M, Yuskaitis C, Weckhuysen S, Prosser B, Son Rigby C, Demarest S, Pierce S, Zhang Y, Møller RS, Bruining H, Poduri A, Zara F, Verhage M, Striano P, Helbig I. Xian J, et al. Among authors: o brien m. Brain. 2022 Jun 3;145(5):1668-1683. doi: 10.1093/brain/awab327. Brain. 2022. PMID: 35190816 Free PMC article.
Diseases of Gastropoda.
O'Brien MF, Pellett S. O'Brien MF, et al. Front Immunol. 2022 Jan 13;12:802920. doi: 10.3389/fimmu.2021.802920. eCollection 2021. Front Immunol. 2022. PMID: 35095886 Free PMC article. Review.
Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia.
Gill S, Vides V, Frey NV, Hexner EO, Metzger S, O'Brien M, Hwang WT, Brogdon JL, Davis MM, Fraietta JA, Gaymon AL, Gladney WL, Lacey SF, Lamontagne A, Mato AR, Maus MV, Melenhorst JJ, Pequignot E, Ruella M, Shestov M, Byrd JC, Schuster SJ, Siegel DL, Levine BL, June CH, Porter DL. Gill S, et al. Among authors: o brien m. Blood Adv. 2022 Nov 8;6(21):5774-5785. doi: 10.1182/bloodadvances.2022007317. Blood Adv. 2022. PMID: 35349631 Free PMC article. Clinical Trial.
Endogenous anticoagulants.
Kubier A, O'Brien M. Kubier A, et al. Among authors: o brien m. Top Companion Anim Med. 2012 May;27(2):81-7. doi: 10.1053/j.tcam.2012.07.003. Epub 2012 Sep 12. Top Companion Anim Med. 2012. PMID: 23031460 Review.
Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621.
O'Brien MM, Ji L, Shah NN, Rheingold SR, Bhojwani D, Yuan CM, Xu X, Yi JS, Harris AC, Brown PA, Borowitz MJ, Militano O, Kairalla J, Devidas M, Raetz EA, Gore L, Loh ML. O'Brien MM, et al. J Clin Oncol. 2022 Mar 20;40(9):956-967. doi: 10.1200/JCO.21.01693. Epub 2022 Jan 10. J Clin Oncol. 2022. PMID: 35007127 Free PMC article.
Protocol for a randomized controlled trial to evaluate a year-long (NICU-to-home) evidence-based, high dose physical therapy intervention in infants at risk of neuromotor delay.
Deng W, Anastasopoulos S, deRegnier RA, Pouppirt N, Barlow AK, Patrick C, O'Brien MK, Babula S, Sukal-Moulton T, Peyton C, Morgan C, Rogers JA, Lieber RL, Jayaraman A. Deng W, et al. Among authors: o brien mk. PLoS One. 2023 Sep 19;18(9):e0291408. doi: 10.1371/journal.pone.0291408. eCollection 2023. PLoS One. 2023. PMID: 37725613 Free PMC article.
Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.
von Pawel J, Jotte R, Spigel DR, O'Brien ME, Socinski MA, Mezger J, Steins M, Bosquée L, Bubis J, Nackaerts K, Trigo JM, Clingan P, Schütte W, Lorigan P, Reck M, Domine M, Shepherd FA, Li S, Renschler MF. von Pawel J, et al. Among authors: o brien me. J Clin Oncol. 2014 Dec 10;32(35):4012-9. doi: 10.1200/JCO.2013.54.5392. Epub 2014 Nov 10. J Clin Oncol. 2014. PMID: 25385727 Clinical Trial.
3,333 results